Format

Send to

Choose Destination
Am J Transplant. 2015 Oct;15(10):2541-51. doi: 10.1111/ajt.13387. Epub 2015 Jul 16.

Cell-Free DNA: An Upcoming Biomarker in Transplantation.

Author information

1
Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, Antwerp, Belgium.
2
Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands.
3
Multiplicom N. V., Niel, Belgium.
4
Department of Nephrology and Hypertension, Antwerp University Hospital, Antwerp, Belgium.

Abstract

After organ transplantation, donor-derived cell-free DNA (ddcfDNA) can be detected in the recipient's blood and urine. Different ddcfDNA quantification techniques have been investigated but a major breakthrough was made with the introduction of digital droplet PCR and massive parallel sequencing creating the opportunity to increase the understanding of ddcfDNA kinetics after transplantation. The observations of increased levels of ddcfDNA during acute rejection and even weeks to months before histologic features of graft rejection point to a possible role of ddcfDNA as an early, noninvasive rejection marker. In this review, we summarize published research on ddcfDNA in the transplantation field thereby elaborating on its clinical utility.

KEYWORDS:

biomarker; clinical research/practice; kidney transplantation/nephrology; molecular biology; molecular biology: DNA; organ transplantation in general; rejection: acute; translational research/science

PMID:
26184824
DOI:
10.1111/ajt.13387
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center